Disease-modifying treatment of Parkinson’s disease by phytochemicals: targeting multiple pathogenic factors
- 15 October 2021
- journal article
- review article
- Published by Springer Nature in Journal of Neural Transmission
- Vol. 129 (5-6) , 737-753
Abstract
Parkinson’s disease is characterized by typical motor symptoms, loss of dopamine neurons in the substantia nigra, and accumulation of Lewy body composed of mutated α-synuclein. However, now it is considered as a generalized disease with multiple pathological features. Present available treatments can ameliorate symptoms at least for a while, but only a few therapies could delay progressive neurodegeneration of dopamine neurons. Lewy body accumulates in peripheral tissues many years before motor dysfunction becomes manifest, suggesting that disease-modifying therapy should start earlier during the premotor stage. Long-termed regulation of lifestyle, diet and supplement of nutraceuticals may be possible ways for the disease-modification. Diet can reduce the incidence of Parkinson’s disease and phytochemicals, major bioactive ingredients of herbs and plant food, modulate multiple pathogenic factors and exert neuroprotective effects in preclinical studies. This review presents mechanisms underlying neuroprotection of phytochemicals against neuronal cell death and α-synuclein toxicity in Parkinson’s disease. Phytochemicals are antioxidants, maintain mitochondrial function and homeostasis, prevent intrinsic apoptosis and neuroinflammation, activate cellular signal pathways to induce anti-apoptotic and pro-survival genes, such as Bcl-2 protein family and neurotrophic factors, and promote cleavage of damaged mitochondria and α-synuclein aggregates. Phytochemicals prevent α-synuclein oligomerization and aggregation, and dissolve preformed α-synuclein aggregates. Novel neuroprotective agents are expected to develop based on the scaffold of phytochemicals permeable across the blood–brain–barrier, to increase the bioavailability, ameliorate brain dysfunction and prevent neurodegeneration.Keywords
Funding Information
- Fundación para la Investigación y la Prevención del Sida en España (8Kk07430)
This publication has 116 references indexed in Scilit:
- Epigallocatechin-3-gallate prevents oxidative phosphorylation deficit and promotes mitochondrial biogenesis in human cells from subjects with Down's syndromeBiochimica et Biophysica Acta (BBA) - Molecular Basis of Disease, 2013
- Caffeic acid phenethyl ester protects nigral dopaminergic neurons via dual mechanisms involving haem oxygenase‐1 and brain‐derived neurotrophic factorBritish Journal of Pharmacology, 2012
- Resveratrol Induces p53-independent, X-linked Inhibitor of Apoptosis Protein (XIAP)-mediated Bax Protein Oligomerization on Mitochondria to Initiate Cytochrome c Release and Caspase ActivationJournal of Biological Chemistry, 2011
- EGCG remodels mature α-synuclein and amyloid-β fibrils and reduces cellular toxicityProceedings of the National Academy of Sciences, 2010
- Wild Type α-Synuclein Is Degraded by Chaperone-mediated Autophagy and Macroautophagy in Neuronal CellsJournal of Biological Chemistry, 2008
- EGCG redirects amyloidogenic polypeptides into unstructured, off-pathway oligomersNature Structural & Molecular Biology, 2008
- Mitochondrial Import and Accumulation of α-Synuclein Impair Complex I in Human Dopaminergic Neuronal Cultures and Parkinson Disease BrainJournal of Biological Chemistry, 2008
- The PINK1/Parkin pathway regulates mitochondrial morphologyProceedings of the National Academy of Sciences, 2008
- Quality control of mitochondria: protection against neurodegeneration and ageingThe EMBO Journal, 2008
- Brain proteasomal function in sporadic Parkinson's disease and related disordersAnnals of Neurology, 2002